Abstracts Archive - Page 472 of 2605 - ACR Meeting Abstracts

Abstract Number: PP08 • ACR Convergence 2023
Finding Gratitude in Adversity: The Impact of Finding the Right Rheumatologist
Yaideliz Acevedo, Global Healthy Living Foundation, Newark, NJ
Background/Purpose: I recall sitting in the doctor's office with my one-month-old baby in his stroller, hearing the words "You have rheumatoid arthritis." At 21, I…
Abstract Number: PP01 • ACR Convergence 2023
You Can’t Get This from a Doctor: The Role of Support Groups for Adults Aged 25-55 Living with Arthritis
Eileen Davidson, Global Healthy Living Foundation, Burnaby, BC, Canada
Background/Purpose: Living with a rheumatic condition comes with unique concerns specific to mental and social health like struggling with fatigue, anxiety, depression, and isolation, all…
Abstract Number: PP14 • ACR Convergence 2023
Putting Lived Experience into Action: Flipping the Script on Living with a Chronic Disease
Natasha Trehan¹ and Naomi Abrahams², ¹University of Ottawa, Take a Pain Check Foundation, Toronto, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Naomi was diagnosed with Juvenile Idiopathic Arthritis (JIA) at the age of 18, after enduring 3 years of misdiagnoses. Similarly, Natasha received a diagnosis…
Abstract Number: PP03 • ACR Convergence 2023
Lupus with Slime: Improve QOL and Increase ROM in SLE with Slime
Amanda Greene, Los Angeles, CA
Background/Purpose: In 1983, over forty years ago, I was diagnosed with Systemic Lupus Erythematosus (SLE). I was immediately prescribed high dose corticosteroids. My body and…
Abstract Number: 2464 • ACR Convergence 2023
B Cells in Anti-tRNA Synthetase Syndrome Patients Show an Activated, Interferon Responsive Signature
Erin Wilfong¹, Leslie Crofford² and Rachel Bonami¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Melbourne, AR
Background/Purpose: Autoantibodies directed against various tRNA synthetases defines the anti-tRNA synthetase syndrome (ARS). While it is unclear if the autoantibodies are directly pathogenic, the efficacy…
Abstract Number: 2467 • ACR Convergence 2023
Quadriceps Muscle Fat Composition but Not Muscle Energetics Is Associated with Knee Osteoarthritis: Initial Results from the Study of Muscle, Mobility, and Aging
Giovanna Distefano¹, Daniel Evans², Peggy Cawthon², John Lynch², Thomas Link², Philip Kramer³, Stephanie Harrison², Bret Goodpaster⁴, Jane Cauley⁵, Theresa Mau², Paul Coen⁴, Lauren Sparks⁴ and Nancy Lane⁶, ¹AventisHealth, Orlando, FL, ²University of California San Francisco, San Francisco, CA, ³Wake Forest, Winston-Salem, NC, ⁴Aventis Health, Orlando, FL, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶University of California, Hillsborough, CA
Background/Purpose: Osteoarthritis (OA) remains the most common cause of joint pain and disability with age, and to date, effective treatments to reduce pain and slow…
Abstract Number: 2474 • ACR Convergence 2023
Uveitis as Predictor of Disease Flare After the First Course of Anti-TNF Withdrawal in Oligo and Polyarticular Juvenile Idiopathic Arthritis: A Multicentric Italian Experience
Ilaria Maccora¹, Valerio Accardo², Marco Cattalini³, ilaria Pagnini⁴, Andrea Taddio⁵, Edoardo Marrani⁶, francesco La Torre⁷, Matteo Trevisan⁸, Maria Vincenza Mastrolia⁹ and Gabriele Simonini¹⁰, ¹PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, ²University of Florence, Florence, Italy, ³Spedali Civili di Brescia, Brescia, Italy, ⁴Meyer Children's Hospital IRCCS, Florence, Italy, ⁵Rheumatology Unit, IRCCS Burlo Garofalo, Trieste, Italy, ⁶University of Florence, Firenze, Italy, ⁷Giovanni XXIII Pediatric Hospital, University of Bari, Bari, Italy, ⁸IRCCS Burlo Garofalo, Trieste, Italy, ⁹NEUROFARBA Department, University of Florence, Florence, Italy, ¹⁰Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence Italy. NeuroFARBA Department, University of Florence, Florence, Italy
Background/Purpose: TNF inhibitors (TNFi) have dramatically changed the prognosis of Juvenile Idiopathic Arthritis (JIA). However, once achieved disease remission, it is not clear how and…
Abstract Number: 2480 • ACR Convergence 2023
Definition of Rheumatoid Arthritis Flare Based on SDAI and CDAI
Victoria Konzett¹, Andreas Kerschbaumer², Josef S Smolen³, Eirik Kristianslund⁴, Sella Provan⁴, Tore Kvien⁵ and Daniel Aletaha⁶, ¹Medical University of Vienna, Wien, Austria, ²Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria
Background/Purpose: Measures of improvement and state of disease activity are well-established in rheumatoid arthritis (RA), whereas distinct classifiers for worsening (“flare”) are lacking to date.…
Abstract Number: 2486 • ACR Convergence 2023
Should SLE Patients Entering Clinical Trials Be Required to Have at Least One BILAG a And/or Two BILAG B Scores?
Ewa Olech¹ and Joan Merrill², ¹IQVIA, Rheumatology Consultants, PLLC, Las Vegas, NV, ²Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: High placebo response rates have challenged interpretation of clinical trial results in SLE and may have contributed to failure of some effective treatments. One…
Abstract Number: 2604 • ACR Convergence 2023
Premature Vascular Smooth Muscle Cells Senescence Driven by Interleukin-6-Mitochondrial STAT3-Mitofusin 2 Signaling in Takayasu’s Arteritis
Chenglong Fang¹, Lihong Du¹, Lili Li², Yuexin Chen³, Zuoguan Chen⁴, Yongjun Li⁴, Jing Li¹, Mengtao Li⁵, xiaofeng Zeng⁶ and Xinping Tian⁵, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ²The State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing, China, ³Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ⁴Department of Vascular Surgery, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China, ⁵Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁶Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Takayasu’s arteritis (TAK) is characterized by persistent vascular inflammation involving aorta and its main branches, which is an important prosenescent factor that in turn…
Abstract Number: PP09 • ACR Convergence 2023
Practicing Mindfulness to Improve Quality of Life
Vanessa Patino-Lydia, Global Healthy Living Foundation, Hallandale, FL
Background/Purpose: I’ve been living with symptoms of PSA and fibromyalgia for over 15 years. Four years ago, after flareup that severely impacted my mobility where…
Abstract Number: PP13 • ACR Convergence 2023
My Four Pillars of Wellness: How Sleep, Diet, Exercise and Stress Reduction Enable Me to Define My Life and not let Sjögren’s Define Me
Lisa Rubenstein, Sjögren's Foundation, Los Angeles, CA

Background/Purpose: Being diagnosed with Sjögren’s has been a life changing event for me.I was diagnosed in 2013 after suffering from various odd ailments. Ultimately, extreme…
Abstract Number: 2456 • ACR Convergence 2023
Lupus Patient Navigator Program to Improve Healthcare Barriers for Minority Patients
Samiha Karim¹, Gary Link¹, Dulaney Wilson¹, Jim Oates¹, Gary Gilkeson¹, Jasvinder Singh² and Diane L. Kamen¹, ¹Medical University of South Carolina, Charleston, SC, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Despite recent progress in diagnosis and treatment of SLE minorities continue to bear the greater burden of disease with disproportionately higher morbidity and mortality.…
Abstract Number: 2118 • ACR Convergence 2023
New Onset Disability in Rheumatoid Arthritis Is an Underrecognized Cardiovascular Risk Factor: A Retrospective Cohort Study Using the CorEvitas Registry
Robert Spandorfer¹, Kevin Kane², George Reed², Dimitrios Pappas², Joel Kremer², Jeffrey Curtis³ and Iris Navarro-Millán⁴, ¹Hospital for Special Surgery, Brooklyn, NY, ²CorEvitas, LLC, Waltham, MA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Weill Cornell Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Cardiovascular disease (CVD) is the most common cause of death among patients with RA. Prior research found a higher rate of CVD events associated…
Abstract Number: 0484 • ACR Convergence 2023
Higher Levels of High-sensitivity CRP Are Associated with Future Risk of Developing Psoriatic Arthritis Among Patients with Psoriasis: A Prospective Cohort Study
Lihi Eder¹, Vinod Chandran², Cheryl Rosen³, Richard J. Cook⁴ and Dafna Gladman⁵, ¹Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, ³Division of Dermatology, Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Simple and accessible biomarkers that predict the development of psoriatic arthritis (PsA) among psoriasis patients are critically needed to improve early detection of high-risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].